Zachary Meyer, MD
Family Medicine · Grand Island, NENPI 1649408428
Payments from drug & device makers
Across 180 payments — averaging $12.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$994
- Novo Nordisk$183
- Lilly USA, LLC$136
- Sanofi-aventis U.S. LLC$131
- Abbott$113
- Amarin Pharma, Inc.$106
- plus $667 from 20 others
What the payments were for
- Food & beverage$2,31699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 115 | $994 |
| Novo Nordisk | 10 | $183 |
| Lilly USA, LLC | 9 | $136 |
| Sanofi-aventis U.S. LLC | 1 | $131 |
| Abbott | 5 | $113 |
| Amarin Pharma, Inc. | 2 | $106 |
| AstraZeneca | 4 | $81 |
| Ipsen Biopharmaceuticals, Inc | 1 | $60 |
| Exact Sciences | 3 | $59 |
| Sanofi Pasteur Inc. | 3 | $52 |
| Pfizer | 3 | $48 |
| GSK | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 3 | $42 |
| Johnson & Johnson | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Merz Pharmaceuticals, LLC | 1 | $30 |
| Seqirus USA Inc | 1 | $26 |
| Novartis | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Merck | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 3 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$2,328 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $106,604 |
| MounjaroTirzepatide | 51 | $73,724 |
| EliquisApixaban | 63 | $70,613 |
| TrulicityDulaglutide | 36 | $52,268 |
| JardianceEmpagliflozin | 59 | $50,887 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $44,489 |
| LinzessLinaclotide | 45 | $34,006 |
| FarxigaDapagliflozin Propanediol | 29 | $29,782 |
| XareltoRivaroxaban | 52 | $26,284 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $23,446 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 53 | $16,655 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $15,990 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 51 | $11,282 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $6,629 |
| Nebivolol Hcl | 128 | $6,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $136 | $125,99287 claims |
| Novo NordiskOzempic | $183 | $106,60461 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $43 | $72,426165 claims |
| PfizerEliquis | $48 | $70,61363 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $81 | $45,77348 claims |
| AbbVieLinzess | $994 | $34,00645 claims |
| Johnson & JohnsonXarelto | $31 | $26,28452 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $131 | $23,44618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Grand Island
- Adam BroszGrand Island$60M
- James OmelGrand Island$67K
- Brandon EssinkCreighton$92.8M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.